- Margo K, Winn R. Testosterone treatments: why, when, and how? Am Fam Physician. 2006;73(9):1591-1598.
Salter CA, Mulhall JP. Guideline of guidelines: testosterone therapy for testosterone deficiency. BJU Int. 2019;124(5):722-729.
Mulhall JP, Trost LW, Brannigan RE. Evaluation and management of testosterone deficiency: AUA guideline. J Urol. 2018;200(2):423-432.
Bhasin S, Brito JP, Cunningham GR. Testosterone therapy in men with hypogonadism: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2018;103(5):1715-1744.
- Tsametis CP, Isidori AM. Testosterone replacement therapy: for whom, when and how? Metabolism. 2018;86:69-78.
Corona G, Rastrelli G, Vignozzi L, Maggi M. Androgens and male sexual function. Best Pract Res Clin Endocrinol Metab. 2022;36(4):101615.
Rodrigues Dos Santos M, Bhasin S. Benefits and risks of testosterone treatment in men with age-related decline in testosterone. Annu Rev Med. 2021;72(1):75-91.
Rastrelli G, Corona G, Maggi M. Both comorbidity burden and low testosterone can explain symptoms and signs of testosterone deficiency in men consulting for sexual dysfunction. Asian J Androl. 2020;22(3):265-273.
Cumarasamy S, Razdan S, Winoker J, Poage W, Crawford ED, Stone N. MP40-06: Assessing the ability of the male androgen deficiency syndrome (MADS) screening questionnaire to predict hypogonadism. J Urol. 2019;201(Suppl 4):e588.
Barbonetti A, D’Andrea S, Francavilla S. Testosterone replacement therapy. Andrology. 2020;8(6):1551-1566.
Rizk PJ, Kohn TP, Pastuszak AW, Khera M. Testosterone therapy improves erectile function and libido in hypogonadal men. Curr Opin Urol. 2017;27(6):511-515.
Qaseem A, Horwitch CA, Vijan S. Testosterone treatment in adult men with age-related low testosterone: a clinical guideline from the American College of Physicians. Ann Intern Med. 2020;172(2):126-133.
Kirlangic OF, Yilmaz-Oral D, Kaya-Sezginer E. The effects of androgens on cardiometabolic syndrome: current therapeutic concepts. Sex Med. 2020;8(2):132-155.
Corona GG, Rastrelli G, Maseroli E, Sforza A, Maggi M. Testosterone replacement therapy and cardiovascular risk: a review. World J Mens Health. 2015;33(3):130-142.
Mohamed O, Freundlich RE, Dakik HK. The quantitative ADAM questionnaire: a new tool in quantifying the severity of hypogonadism. Int J Impot Res. 2010;22(1):20-24.
Krzastek SC, Smith RP. Non-testosterone management of male hypogonadism: an examination of the existing literature. Transl Androl Urol. 2020;9(Suppl 2):S160-S170.
Fink J, Schoenfeld BJ, Hackney AC, Maekawa T, Horie S. Human chorionic gonadotropin treatment: a viable option for management of secondary hypogonadism and male infertility. Expert Rev Endocrinol Metab. 2021;16(1):1-8.
Burnett-Bowie SA, McKay EA, Lee H, Leder BZ. Effects of aromatase inhibition on bone mineral density and bone turnover in older men with low testosterone levels. J Clin Endocrinol Metab. 2009;94(12):4785-4792.
Taylor F, Levine L. Clomiphene citrate and testosterone gel replacement therapy for male hypogonadism: efficacy and treatment cost. J Sex Med. 2010;7(1 Pt 1):269-276.
Moran LJ, Brinkworth GD, Martin S. Long-term effects of a randomised controlled trial comparing high protein or high carbohydrate weight loss diets on testosterone, SHBG, erectile and urinary function in overweight and obese men. PLoS One. 2016;11(9):e0161297.
Pastuszak AW, Moon YM, Scovell J. Poor sleep quality predicts hypogonadal symptoms and sexual dysfunction in male nonstandard shift workers. Urology. 2017;102:121-125.
Rigon FA, Ronsoni MF, Hohl A, van de Sande-Lee S. Effects of bariatric surgery in male obesity-associated hypogonadism. Obes Surg. 2019;29(7):2115-2125.
Clemesha CG, Thaker H, Samplaski MK. ‘Testosterone boosting’ supplements composition and claims are not supported by the academic literature. World J Mens Health. 2020;38(1):115-122.
Shelley BM, Sussman AL, Williams RL, Segal AR, Crabtree BF. ‘They don’t ask me so I don’t tell them’: patient-clinician communication about traditional, complementary, and alternative medicine. Ann Fam Med. 2009;7(2):139-147.
Smith SJ, Lopresti AL, Teo SYM, Fairchild TJ. Examining the effects of herbs on testosterone concentrations in men: a systematic review. Adv Nutr. 2021;12(3):744-765.
Kovac JR, Pan M, Arent S, Lipshultz LI. Dietary adjuncts for improving testosterone levels in hypogonadal males. Am J Men Health. 2016;10(6):NP109-NP117.
Amano T, Imao T, Takemae K. Clinical efficacy of Japanese traditional herbal medicine (Kampo) in patients with late-onset hypogonadism. Aging Male. 2010;13(3):166-173.
Committee on Gynecologic Practice and the American Society for Reproductive Medicine Practice Committee. Committee Opinion No. 532: compounded bioidentical menopausal hormone therapy. Obstet Gynecol. 2012;120(2 Pt 1):411-415.
Hamoda H, Mukherjee A, Morris E. Optimising the menopause transition: joint position statement by the British Menopause Society, Royal College of Obstetricians and Gynaecologists and Society for Endocrinology on best practice recommendations for the care of women experiencing the menopause. Post Reprod Health. 2022;28(3):121-122.
Kaunitz AM, Manson JE. Management of menopausal symptoms. Obstet Gynecol. 2015;126(4):859-876.
Harlow SD, Gass M, Hall JE. Executive summary of the Stages of Reproductive Aging Workshop + 10: addressing the unfinished agenda of staging reproductive aging. J Clin Endocrinol Metab. 2012;97(4):1159-1168.
Sarri G, Davies M, Lumsden MA. Diagnosis and management of menopause: summary of NICE guidance. BMJ. 2015;351:h5746.
Stuenkel CA, Davis SR, Gompel A. Treatment of symptoms of the menopause: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2015;100(11):3975-4011.
ACOG committee opinion no. 557: management of acute abnormal uterine bleeding in nonpregnant reproductive-aged women. Obstet Gynecol. 2013;121(4):891-896.
- 2019 Surveillance of Menopause: Diagnosis and Management (NICE Guideline NG23). London: National Institute for Health and Care Excellence (NICE); 2019. https://www.ncbi.nlm.nih.gov/books/NBK563593/
Marjoribanks J, Farquhar C, Roberts H, Lethaby A, Lee J. Long-term hormone therapy for perimenopausal and postmenopausal women. Cochrane Database Syst Rev. 2017(1):CD004143.
“The 2022 Hormone Therapy Position Statement of The North American Menopause Society” Advisory Panel. The 2022 hormone therapy position statement of The North American Menopause Society. Menopause. 2022;29(7):767-794.
ACOG Committee Opinion No. 565: Hormone therapy and heart disease. Obstet Gynecol. 2013;121(6):1407-1410.
Reid R, Abramson BL, Blake J. Managing menopause. J Obstet Gynaecol Can. 2014;36(9):830-833.
Mangione CM, Barry MJ, Nicholson WK. Hormone therapy for the primary prevention of chronic conditions in postmenopausal persons: US Preventive Services Task Force Recommendation Statement. JAMA. 2022;328(17):1740-1746.
Boardman HM, Hartley L, Eisinga A. Hormone therapy for preventing cardiovascular disease in post-menopausal women. Cochrane Database Syst Rev. 2015(3):CD002229.
Kim JE, Chang JH, Jeong MJ. A systematic review and meta-analysis of effects of menopausal hormone therapy on cardiovascular diseases. Sci Rep. 2020;10(1):20631.
Nudy M, Chinchilli VM, Foy AJ. A systematic review and meta-regression analysis to examine the ‘timing hypothesis’ of hormone replacement therapy on mortality, coronary heart disease, and stroke. Int J Cardiol Heart Vasc. 2019;22:123-131.
Treatment of urogenital symptoms in individuals with a history of estrogen-dependent breast cancer: clinical consensus. Obstet Gynecol. 2021;138(6):950-960.
Shepherd HL, Barratt A, Trevena LJ. Three questions that patients can ask to improve the quality of information physicians give about treatment options: a cross-over trial. Patient Educ Couns. 2011;84(3):379-385.
Manson JE, Chlebowski RT, Stefanick ML. Menopausal hormone therapy and health outcomes during the intervention and extended poststopping phases of the Women’s Health Initiative randomized trials. JAMA. 2013;310(13):1353-1368.
Vinogradova Y, Coupland C, Hippisley-Cox J. Use of hormone replacement therapy and risk of venous thromboembolism: nested case-control studies using the QResearch and CPRD databases. BMJ. 2019;364:k4810. 2019;364:l162.
Rossouw JE, Anderson GL, Prentice RL. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women’s Health Initiative randomized controlled trial. JAMA. 2002;288(3):321-333.
Collaborative Group on Hormonal Factors in Breast Cancer. Type and timing of menopausal hormone therapy and breast cancer risk: individual participant meta-analysis of the worldwide epidemiological evidence. Lancet. 2019;394(10204):1159-1168.
Liu B, Beral V, Balkwill A, Green J, Sweetland S, Reeves G; Million Women Study Collaborators. Gallbladder disease and use of transdermal versus oral hormone replacement therapy in postmenopausal women: prospective cohort study. BMJ. 2008;337:a386.
Long CY, Liu CM, Hsu SC, Wu CH, Wang CL, Tsai EM. A randomized comparative study of the effects of oral and topical estrogen therapy on the vaginal vascularization and sexual function in hysterectomized postmenopausal women. Menopause. 2006;13(5):737-743.
Santoro N, Worsley R, Miller KK, Parish SJ, Davis SR. Role of estrogens and estrogen-like compounds in female sexual function and dysfunction. J Sex Med. 2016;13(3):305-316.
Mitchell CM, Reed SD, Diem S. Efficacy of vaginal estradiol or vaginal moisturizer vs placebo for treating postmenopausal vulvovaginal symptoms: a randomized clinical trial. JAMA Intern Med. 2018;178(5):681-690.
Hendrix SL, Cochrane BB, Nygaard IE. Effects of estrogen with and without progestin on urinary incontinence. JAMA. 2005;293(8):935-948.
Ferrante KL, Wasenda EJ, Jung CE, Adams-Piper ER, Lukacz ES. Vaginal estrogen for the prevention of recurrent urinary tract infection in postmenopausal women: a randomized clinical trial. Female Pelvic Med Reconstr Surg. 2021;27(2):112-117.
Cody JD, Jacobs ML, Richardson K, Moehrer B, Hextall A. Oestrogen therapy for urinary incontinence in post-menopausal women. Cochrane Database Syst Rev. 2012(10):CD001405.
Daley A, Stokes-Lampard H, Thomas A, MacArthur C. Exercise for vasomotor menopausal symptoms. Cochrane Database Syst Rev. 2014(11):CD006108.
Susanti HD, Sonko I, Chang PC, Chuang YH, Chung MH. Effects of yoga on menopausal symptoms and sleep quality across menopause statuses: a randomized controlled trial. Nurs Health Sci. 2022;24(2):368-379.
Greendale GA, Gold EB. Lifestyle factors: are they related to vasomotor symptoms and do they modify the effectiveness or side effects of hormone therapy?. Am J Med. 2005;118(Suppl 12B):148-154.
Barnard ND, Kahleova H, Holtz DN. A dietary intervention for vasomotor symptoms of menopause: a randomized, controlled trial. Menopause. 2023;30(1):80-87.
Guthrie KA, LaCroix AZ, Ensrud KE. Pooled analysis of six pharmacologic and nonpharmacologic interventions for vasomotor symptoms. Obstet Gynecol. 2015;126(2):413-422.
World Health Organization. Ageing and health. https://www.who.int/news-room/fact-sheets/detail/ageing-and-health
- Medina L, Sabo S, Vespa J. Living Longer: Historical and Projected Life Expectancy in the United States, 1960 to 2060. Population Estimates and Projections. US Census Bureau; 2020. https://www.census.gov/content/dam/Census/library/publications/2020/demo/p25-1145.pdf
Friedman SM, Mulhausen P, Cleveland ML. Healthy aging: American Geriatrics Society white paper executive summary. J Am Geriatr Soc. 2019;67(1):17-20.
- van den Beld AW, Lamberts SWJ. Endocrinology and aging. In: Melmed S, Auchus R, Goldfine A, Koenig R, Rosen C, Williams R, eds. Williams Textbook of Endocrinology. 14th ed. Elsevier; 2020: 1179-1194.
Samaras N, Papadopoulou MA, Samaras D, Ongaro F. Off-label use of hormones as an antiaging strategy: a review. Clin Interv Aging. 2014;9:1175-1186.
Reddy SSK, Chaiban JT. The endocrinology of aging: a key to longevity “Great Expectations.”. Endocr Pract. 2017;23(9):1107-1116.
Diamanti-Kandarakis E, Dattilo M, Macut D. Mechanisms in endocrinology: aging and anti-aging: a Combo-Endocrinology overview. Eur J Endocrinol. 2017;176(6):R283-R308.
Allison R, Assadzandi S, Adelman M. Frailty: evaluation and management. Am Fam Physician. 2021;103(4):219-226.
Xue QL. The frailty syndrome: definition and natural history. Clin Geriatr Med. 2011;27(1):1-15.
- Kim MI. Hypothyroidism in Older Adults. Endotext. MDText.com, Inc.; 2000. https://www.ncbi.nlm.nih.gov/books/NBK279005/
- Lechan RM. Neuroendocrinology. In: Melmed S, Auchus R, Goldfine A, Koenig R, Rosen C, Williams R, eds. Williams Textbook of Endocrinology. 14th ed. Elsevier; 2020:114-183.
Melmed S. Pathogenesis and diagnosis of growth hormone deficiency in adults. N Engl J Med. 2019;380(26):2551-2562.
Bartke A. Growth hormone and aging: updated review. World J Mens Health. 2019;37(1):19-30.
Melmed S. Idiopathic adult growth hormone deficiency. J Clin Endocrinol Metab. 2013;98(6):2187-2197.
Fleseriu M, Hashim IA, Karavitaki N. Hormonal replacement in hypopituitarism in adults: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2016;101(11):3888-3921.
Yuen KCJ, Biller BMK, Radovick S. American Association of Clinical Endocrinologists and American College of Endocrinology guidelines for management of growth hormone deficiency in adults and patients transitioning from pediatric to adult care. Endocr Pract. 2019;25(11):1191-1232.
Hartman ML, Crowe BJ, Biller BM, Ho KK, Clemmons DR, Chipman JJ. Which patients do not require a GH stimulation test for the diagnosis of adult GH deficiency?. J Clin Endocrinol Metab. 2002;87(2):477-485.
Liu H, Bravata DM, Olkin I. Systematic review: the safety and efficacy of growth hormone in the healthy elderly. Ann Intern Med. 2007;146(2):104-115.
Friedman SD, Baker LD, Borson S. Growth hormone-releasing hormone effects on brain γ-aminobutyric acid levels in mild cognitive impairment and healthy aging. JAMA Neurol. 2013;70(7):883-890.
Melmed S. Supplemental growth hormone in healthy adults: the endocrinologist’s responsibility. Nat Clin Pract Endocrinol Metab. 2006;2(3):119.
Clemmons DR, Molitch M, Hoffman AR. Growth hormone should be used only for approved indications. J Clin Endocrinol Metab. 2014;99(2):409-411.
- Genazzani AD, Lanzoni C, Genazzani AR. Might DHEA be considered a beneficial replacement therapy in the elderly? Drugs Aging. 2007;24(3):173-185.
Maninger N, Wolkowitz OM, Reus VI, Epel ES, Mellon SH. Neurobiological and neuropsychiatric effects of dehydroepiandrosterone (DHEA) and DHEA sulfate (DHEAS). Front Neuroendocrinol. 2009;30(1):65-91.
Samaras N, Samaras D, Frangos E, Forster A, Philippe J. A review of age-related dehydroepiandrosterone decline and its association with well-known geriatric syndromes: is treatment beneficial?. Rejuvenation Res. 2013;16(4):285-294.
Yamaji T, Ishibashi M, Takaku F, Itabashi A, Katayama S, Ishii J. Serum dehydroepiandrosterone sulfate concentrations in secondary adrenal insufficiency. J Clin Endocrinol Metab. 1987;65(3):448-451.
Bornstein SR, Allolio B, Arlt W. Diagnosis and treatment of primary adrenal insufficiency: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2016;101(2):364-389.
Labrie F, Archer DF, Koltun W; VVA Prasterone Research Group. Efficacy of intravaginal dehydroepiandrosterone (DHEA) on moderate to severe dyspareunia and vaginal dryness, symptoms of vulvovaginal atrophy, and of the genitourinary syndrome of menopause. Menopause. 2016;23(3):243-256.
Hayes R, Birch M. Prasterone (Intrarosa) for dyspareunia. Am Fam Physician. 2019;99(2):117-122.
Benloucif S, Burgess HJ, Klerman EB. Measuring melatonin in humans. J Clin Sleep Med. 2008;4(1):66-69.
Rzepka-Migut B, Paprocka J. Melatonin-measurement methods and the factors modifying the results. a systematic review of the literature. Int J Environ Res Public Health. 2020;17(6):1916.
Hardeland R. Aging, melatonin, and the pro- and anti-inflammatory networks. Int J Mol Sci. 2019;20(5):1223.
Karasek M. Melatonin, human aging, and age-related diseases. Exp Gerontol. 2004;39(11-12):1723-1729.
Rehman HU, Masson EA. Neuroendocrinology of ageing. Age Ageing. 2001;30(4):279-287.
Hardeland R. Neurobiology, pathophysiology, and treatment of melatonin deficiency and dysfunction. ScientificWorldJournal. 2012;2012:640389.
Polimeni G, Esposito E, Bevelacqua V, Guarneri C, Cuzzocrea S. Role of melatonin supplementation in neurodegenerative disorders. Front Biosci. 2014;19(3):429-446.
Pandi-Perumal SR, BaHammam AS, Brown GM. Melatonin antioxidative defense: therapeutical implications for aging and neurodegenerative processes. Neurotox Res. 2013;23(3):267-300.
Milani M, Sparavigna A. Antiaging efficacy of melatonin-based day and night creams: a randomized, split-face, assessor-blinded proof-of-concept trial. Clin Cosmet Investig Dermatol. 2018;11:51-57.
Meng X, Li Y, Li S. Dietary sources and bioactivities of melatonin. Nutrients. 2017;9(4):367.
Anghel L, Baroiu L, Popazu CR. Benefits and adverse events of melatonin use in the elderly [review]. Exp Ther Med. 2022;23(3):219.
Klein DA, Paradise SL, Goodwin ET. Caring for transgender and gender-diverse persons: what clinicians should know. Am Fam Physician. 2018;98(11):645-653.
Indigenous Futures Project. From protests to the ballot box and beyond: building indigenous power. https://live-cnay.pantheonsite.io/wp-content/uploads/2020/12/indigenous_Futures_Survey_report_finalforemail.pdf
Marra J, Law AMY, Conlon E. Clinical considerations in caring for transgender athletes. Am Fam Physician. 2021;103(9):518-520.
Meerwijk EL, Sevelius JM. Transgender population size in the United States: a meta-regression of population-based probability samples. Am J Public Health. 2017;107(2):e1-e8.
- Herman JL, Flores AR, O’Neill KK. How Many Adults and Youth Identify as Transgender in the United States? Williams Institute, UCLA School of Law; 2022. https://williamsinstitute.law.ucla.edu/wp-content/uploads/Trans-Pop-Update-Jun-2022.pdf
National LGBTQIA+ Health Education Center. Ten strategies for creating inclusive health care environments for LGBTQIA+ people. https://www.lgbtqiahealtheducation.org/wp-content/uploads/2021/05/Ten-Strategies-for-Creating-Inclusive-Health-Care-Environments-for-LGBTQIA-People-Brief.pdf
- Deutsch MB. Guidelines for the Primary and Gender-Affirming Care of Transgender and Gender Nonbinary People. 2nd ed. Center of Excellence for Transgender Health at University of California San Francisco; 2016. https://transcare.ucsf.edu/sites/transcare.ucsf.edu/files/Transgender-PGACG-6-17-16.pdf
Coleman E, Radix AE, Bouman WP. Standards of Care for the Health of Transgender and Gender Diverse People, Version 8. Int J Transgend Health. 2022;23(Suppl 1):S1-S259.
Hembree WC, Cohen-Kettenis PT, Gooren L. Endocrine treatment of gender-dysphoric/gender-incongruent persons: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2017;102(11):3869-3903. 2018;103(7):2758-2759.
T’Sjoen G, Arcelus J, Gooren L, Klink DT, Tangpricha V. Endocrinology of transgender medicine. Endocr Rev. 2019;40(1):97-117.
- Emmanuel M, Bokor BR. Tanner stages. StatPearls. StatPearls Publishing; 2023. https://www.ncbi.nlm.nih.gov/books/NBK470280/
Transgender Medical Consultation Service. TransLine. Gender affirming hormone therapy prescriber guidelines. https://transline.zendesk.com/hc/en-us/article_attachments/360047702053/TransLine_HRT_Guidelines_FINAL.pdf
Milionis C, Ilias I, Koukkou E. Progesterone in gender-affirming therapy of trans women. World J Biol Chem. 2022;13(3):66-71.
- US Public Health Service. Preexposure Prophylaxis for the Prevention of HIV Infection in the United States—2021 Update: A Clinical Practice Guideline. Centers for Disease Control and Prevention, Dept of Health and Human Services; 2018. https://www.cdc.gov/hiv/pdf/risk/prep/cdc-hiv-prep-guidelines-2021.pdf
Rothman MS, Iwamoto SJ. Bone health in the transgender population. Clin Rev Bone Miner Metab. 2019;17(2):77-85.
Movement Advancement Project. Healthcare laws and policies. https://www.lgbtmap.org/equality-maps/healthcare_laws_and_policies
- Gomez I, Ranji U. Salganicoff. Update on Medicaid coverage of gender-affirming health services. KFF; 2022. https://www.kff.org/womens-health-policy/issue-brief/update-on-medicaid-coverage-of-gender-affirming-health-services/
- Centers for Medicare & Medicaid Services. Transgender health care. HealthCare.gov. https://www.healthcare.gov/transgender-health-care/
American Medical Association. Issue Brief: Health insurance coverage for gender affirming care of transgender patients. https://www.ama-assn.org/system/files/2019-03/transgender-coverage-issue-brief.pdf
Movement Advancement Project. Healthcare laws and policies. https://www.lgbtmap.org/equality-maps/healthcare_laws_and_policies
- Dawson L, Kates J, Musumeci M. Youth access to gender affirming care: the federal and state policy landscape. KFF; 2022. https://www.kff.org/other/issue-brief/youth-access-to-gender-affirming-care-the-federal-and-state-policy-landscape/
Human Rights Campaign. For the first time ever, Human Rights Campaign officially declares “state of emergency” for LGBTQ+ Americans; issues national warning and guidebook to ensure safety for LGBTQ+ residents and travelers. https://www.hrc.org/press-releases/for-the-first-time-ever-human-rights-campaign-officially-declares-state-of-emergency-for-lgbtq-americans-issues-national-warning-and-guidebook-to-ensure-safety-for-lgbtq-residents-and-travelers
